日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lithography-Defined Semiconductor Moirés with Anomalous In-Gap Quantum Hall States

具有异常带隙量子霍尔态的光刻定义半导体莫尔条纹

Pan, Wei; Burckel, D Bruce; Spataru, Catalin D; Sapkota, Keshab R; Muhowski, Aaron J; Hawkins, Samuel D; Klem, John F; Smith, Layla S; Temple, Doyle A; Enderson, Zachery A; Jiang, Zhigang; Thirunavukkuarasu, Komalavalli; Xiang, Li; Ozerov, Mykhaylo; Smirnov, Dmitry; Niu, Chang; Ye, Peide D; Pai, Praveen; Zhang, Fan

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia

LP-118 是一种新型 B 细胞淋巴瘤 2/超大抑制剂,在维奈克拉耐药性慢性淋巴细胞白血病模型中表现出疗效

Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, KerryA Rogers, Adam S Kittai, Seema A Bhat

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

nemtabrutinib 和 venetoclax 联合治疗慢性淋巴细胞白血病的临床前评价

Muhowski, Elizabeth M; Ravikrishnan, Janani; Gordon, Britten; Yu, Lianbo; Misra, Shrilekha; Walker, Brandi; Eathiraj, Sudharshan; Sampath, Deepa; Rogers, Kerry A; Byrd, John C; Woyach, Jennifer A

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

通过 CYP3A 抑制有意调节伊布替尼药代动力学

Eric D Eisenmann, Qiang Fu, Elizabeth M Muhowski, Yan Jin, Muhammad Erfan Uddin, Dominique A Garrison, Robert H Weber, Jennifer Woyach, John C Byrd, Alex Sparreboom, Sharyn D Baker

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

靶向磷脂酰肌醇 3 激酶-β 和 -δ 治疗弥漫性大 B 细胞淋巴瘤中的布鲁顿酪氨酸激酶耐药

Neeraj Jain, Satishkumar Singh, Georgios Laliotis, Amber Hart, Elizabeth Muhowski, Kristyna Kupcova, Tereza Chrbolkova, Tamer Khashab, Sayan Mullick Chowdhury, Anuvrat Sircar, Fazal Shirazi, Ram Kumar Singh, Lapo Alinari, Jiangjiang Zhu, Ondrej Havranek, Philip Tsichlis, Jennifer Woyach, Robert Baio

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

BTK 抑制剂 ARQ 531 靶向治疗对伊布替尼耐药的慢性淋巴细胞白血病 (CLL) 和 Richter 转化

Sean D Reiff, Rose Mantel, Lisa L Smith, J T Greene, Elizabeth M Muhowski, Catherine A Fabian, Virginia M Goettl, Minh Tran, Bonnie K Harrington, Kerry A Rogers, Farrukh T Awan, Kami Maddocks, Leslie Andritsos, Amy M Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, 

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

GDC-0853 对 C481S Bruton 酪氨酸激酶的非共价抑制:伊布替尼耐药 CLL 的新治疗策略

Sean D Reiff, Elizabeth M Muhowski, Daphne Guinn, Amy Lehman, Catherine A Fabian, Carolyn Cheney, Rose Mantel, Lisa Smith, Amy J Johnson, Wendy B Young, Adam R Johnson, Lichuan Liu, John C Byrd, Jennifer A Woyach